Status and phase
Conditions
Treatments
About
The main objective is to assess the variation in plasma levels of cathelicidin before and after influenza vaccination.
All bibliographic data suggests that supplementation vitamin D in the elderly often deficient in this vitamin may have a double interest:
The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system.
Full description
CONDUCT OF THE STUDY:
Visit 1: selection of subjects (CPC / CIC-Inserm CIC501)
Visit 2: randomization (CPC / CIC-Inserm CIC501)
Start of vitamin D supplementation or placebo
Subjects with vitamin D levels <30ng/mL will be randomized into two groups:
It will be given to the patient 4 bulbs product (vitamin D or placebo) for supplementation for 2 months (1 / 15 days).
Call subjects at 4 weeks of vitamin supplementation / placebo to assess the clinical safety of the product, as well as compliance with the instructions of supplementation.
Visit 3: After seven weeks of vitamin supplementation / placebo (CPC / CIC-Inserm CIC501)
For the placebo group given two bulbs for the third month placebo placebo supplementation.
For the VitD group: dose adjustment according to the following scheme:
End of the study Removal of anonymity for physician investigators to propose a vitamin D the subjects who received placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
37 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal